Appendix Table A1.

 Differences in Distributions of Inflammatory Biomarker Concentrations Associated with Daily Cannabis Use (Compared with No Use) from Multivariable Generalized Gamma Regressions

Biomarker	% Shift	95% LL	95% UL	p	q
BAFF	9.0%	1.7%	16.9%	0.015	0.006
CCL11	8.9%	−2.4%	21.4%	0.127	0.017
CCL13	0.1%	−9.7%	11.0%	0.981	0.050
CCL17	11.1%	−5.6%	30.7%	0.206	0.021
CCL2	4.2%	−5.9%	15.2%	0.430	0.035
CCL4	7.0%	−9.3%	26.3%	0.420	0.033
CRP	3.8%	−21.4%	37.1%	0.794	0.046
CXCL10	−8.1%	−21.2%	7.3%	0.285	0.023
CXCL13	6.2%	−2.3%	15.4%	0.155	0.019
GM-CSF	15.0%	−12.1%	50.5%	0.308	0.025
IFN-γ	−2.2%	−22.9%	24.1%	0.857	0.048
IL-10	22.4%	1.9%	47.0%	0.031	0.008
IL-12p70	8.4%	−16.5%	40.8%	0.543	0.038
IL-1β	53.8%	18.2%	99.9%	0.001	0.002
IL-2	35.9%	8.9%	69.6%	0.007	0.004
IL-6	19.8%	1.6%	41.2%	0.031	0.010
IL-8	15.6%	0.4%	33.1%	0.044	0.013
sCD14	3.7%	−3.7%	11.6%	0.341	0.029
sCD27	−2.0%	−10.5%	7.2%	0.658	0.044
sGP130	−2.2%	−7.4%	3.2%	0.418	0.031
sIL-2Rα	2.4%	−6.3%	12.0%	0.601	0.040
sIL-6R	−6.1%	−12.4%	0.5%	0.070	0.015
sTNFR2	−2.1%	−10.4%	7.0%	0.643	0.042
TNF-α	5.4%	−5.3%	17.4%	0.334	0.027

Models are adjusted for HIV serostatus, age, race, HCV infection, cigarette smoking, obesity, diabetes, and anemia. q-Values for controlling false discovery rate at 5%; bold italics indicate p-value < q-value.

95% LL, lower bound of 95% confidence limit; 95% UL, upper bound of 95% confidence limit; HCV, hepatitis C virus.